PHIO Fundamental Analysis - PHIO PHARMACEUTICALS CORP

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PHIO. PHIO was compared to 549 industry peers in the Biotechnology industry. While PHIO seems to be doing ok healthwise, there are quite some concerns on its profitability. PHIO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PHIO had negative earnings in the past year.

PHIO had a negative operating cash flow in the past year.

In the past 5 years PHIO always reported negative net income.

PHIO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -62.69%, PHIO perfoms like the industry average, outperforming 42.62% of the companies in the same industry.

PHIO has a Return On Equity of -70.18%. This is comparable to the rest of the industry: PHIO outperforms 56.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	-62.69%
ROE	-70.18%
ROIC	N/A

ROA(3y)-110.57%

ROA(5y)-88.07%

ROE(3y)-133.2%

ROE(5y)-105.54%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PHIO has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, PHIO has more shares outstanding

There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PHIO has an Altman-Z score of -13.76. This is a bad value and indicates that PHIO is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -13.76, PHIO is doing worse than 78.32% of the companies in the same industry.

There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-13.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 9.36 indicates that PHIO has no problem at all paying its short term obligations.

The Current ratio of PHIO (9.36) is better than 79.78% of its industry peers.

PHIO has a Quick Ratio of 9.36. This indicates that PHIO is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 9.36, PHIO is doing good in the industry, outperforming 79.96% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	9.36
Quick Ratio	9.36

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PHIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.88%, which is quite impressive.

EPS 1Y (TTM)83.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87.52%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHIO will show a very strong growth in Earnings Per Share. The EPS will grow by 24.62% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y71.67%

EPS Next 2Y36.09%

EPS Next 3Y24.62%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHIO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHIO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PHIO's earnings are expected to grow with 24.62% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.09%

EPS Next 3Y24.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PHIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (8/22/2025, 8:00:00 PM)

After market: 2.05 -0.04 (-1.91%)

2.09

+0.02 (+0.97%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-12 2025-08-12

Earnings (Next)11-12 2025-11-12

Inst Owners16.78%

Inst Owner Change63.7%

Ins Owners0.94%

Ins Owner Change2.29%

Market Cap11.98M

Analysts82.86

Price Target14.28 (583.25%)

Short Float %12.62%

Short Ratio0.58

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)250%

EPS NQ rev (1m)-15%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-141.86%

EPS NY rev (3m)-141.86%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-100%

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.19
P/tB	1.19
EV/EBITDA	N/A

EPS(TTM)-6.48

EYN/A

EPS(NY)-0.96

Fwd EYN/A

FCF(TTM)-1.25

FCFYN/A

OCF(TTM)-1.25

OCFYN/A

SpS0

BVpS1.76

TBVpS1.76

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-62.69%
ROE	-70.18%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-110.57%

ROA(5y)-88.07%

ROE(3y)-133.2%

ROE(5y)-105.54%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	-120%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.36
Quick Ratio	9.36
Altman-Z	-13.76

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)59%

Cap/Depr(5y)53.61%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)83.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87.52%

EPS Next Y71.67%

EPS Next 2Y36.09%

EPS Next 3Y24.62%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.12%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-10.81%

EBIT Next 3Y-12.37%

EBIT Next 5YN/A

FCF growth 1Y39.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y39.05%

OCF growth 3YN/A

OCF growth 5YN/A

PHIO PHARMACEUTICALS CORP (PHIO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens